Endo Health reports Q3 Branded pharmaceutical sales down 2% to $417M Net sales of Opana ER decreased 36% for the third quarter on 33 percent lower prescriptions. The decrease in Opana ER net sales is primarily a result of the first quarter supply disruption due to the Novartis plant closure in Lincoln, Neb., and a slower return to growth for Opana ER.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo Health subsidiary receives CE Mark of RetroArc system American Medical Systems, an Endo Health Solutions subsidiary, announced CE Mark of its RetroArc Retropubic Sling System for treatment of female stress urinary incontinence. The system maintains familiar features of transvaginal retropubic sling systems while incorporating new enhancements and the ability to make fine-tuned adjustments to better meet the needs of physicians, the company said.